The current price of IRD is $4.01 — it has decreased by 6.21% since the previous close. Data as of Nov 5, 2026.
IRD is up 11.87% over the past week, down 8.56% over the past month and up 88.92% over the past year. The price is below its 200-day moving average of $4.21.
Analysts' average 12-month price target for IRD is $12.60, which implies 214.61% upside from the current price. Individual estimates range from $8.00 to $20.00.
Opus Genetics, Inc. has a market capitalization of $333.2M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Opus Genetics, Inc. posted a loss of $0.14 per share against an estimate of -$0.1567, beating expectations by 10.64%. Upcoming reports are listed in the earnings calendar.
Opus Genetics, Inc. reported revenue of $755K in its most recent quarter, which has decreased by 73.80% compared with the same quarter a year earlier. Analysts had expected $2.63M.
Opus Genetics, Inc. has not paid any dividends over the past year.
Companies most comparable to Opus Genetics, Inc. include Agenus Inc., Alector, Inc., Inovio Pharmaceuticals, Inc., TuHURA Biosciences, Inc. and Seer, Inc.
In the latest trading session IRD moved between $3.80 and $4.26, a range of 11.61% of its current price.
Over the past 52 weeks IRD has traded between $1.70 and $7.07. The current price is 43.35% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.